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Noninfectious pulmonary syndromes (NIPS) frequently complicate allogeneic stem cell transplantation (allo-
SCT). Themost commonand serious is the bronchiolitis obliterans syndrome, characterized by irreversibleﬁxed
airﬂow obstruction, impaired quality of life, and a high mortality. Treatment for established symptomatic
disease is relatively ineffective. We therefore sought to identify potential predictive factors for development of
NIPS, which may identify patients at risk in whom earlier intervention may be of beneﬁt. Spirometry and
diffusing capacity for carbon monoxide were performed before allo-SCT, day 100, and 1 year after allo-SCT. We
retrospectively analyzed spirometry in consecutive patients having allo-SCT from 2004 to 2010, along with
computed tomography and bronchoalveolar lavage results to identify cases of NIPS. Cases of bronchiolitis
obliterans syndromewere deﬁned as per currentNational Institutes of Health consensus guidelines. Spirometry
results and baseline variables were compared between patients with and without NIPS to identify early pre-
dictors and risk factors for NIPS. Of 235 assessable patients, 23 (9.8%) developed NIPS. Median time of onset was
day 367 (interquartile range [IQR],144 to 544 days). Changes in forced expiratory volume in 1 second (DFEV1.0)
was the best predictor of later NIPS development. Median DFEV1.0 from pretransplant to day 100 in patients
later developing NIPS was 12% (IQR, 25% to 1%) versus 1% (IQR, 7% to þ6%) in unaffected patients,
P¼ .002. From pretransplant to 1 year, DFEV1.0 was19% (IQR,37% to6%) versus3% (IQR,10% toþ4%) in
patients later developingNIPS and unaffected patients, respectively, P< .001. Busulfan-based, but not total body
irradiationebased, conditioning increased the risk of NIPS (hazard ratio, 9.4 [3.4 to 23.9], P < .001). No cases of
NIPS were seen in the 53 patients who received in vivo T cell depletion with antithymocyte globulin (ATG,
Genzyme Transplant, Cambridge, MA) (P< .0001). NIPS were associated with high transplant-relatedmortality
relative to unaffected patients (hazard ratio, 6.6 [2.5 to 16.4], P < .001). Spirometry is a potentially useful
screening test for identiﬁcation of presymptomatic NIPS. We recommend 3-monthly spirometry surveillance
for up to 2 years post-transplant. Our ﬁndings require prospective validation to identify patients in whom
earlier intervention may potentially modify the natural history of this disease.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Pulmonary complications occur in 25% to 50% of alloge-
neic stem cell transplantation (allo-SCT) recipients, with 50%
of these being noninfectious in etiology [1]. Of noninfectious
pulmonary complications, both acute and subacute chronic
disorders are recognized. The idiopathic pneumonia syn-
drome,which presentswithin the ﬁrst 120 days postallograft,
is associated with a fulminant course, poor response to
therapy, and a high mortality of 60% to 80%. Although the
precise etiology is unknown, idiopathic pneumonia syn-
drome is associated with grades III to IV acute graft-versus-
host disease (aGVHD) [2].ledgments on page 786.
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dromes (NIPS) may be divided into 2 distinct syndromes:
bronchiolitis obliterans syndrome (BOS) and cryptogenic
organizing pneumonia (COP) (formerly termed bronchiolitis
obliterans organizing pneumonia or BOOP). BOS is an
obstructive process that targets terminal bronchioles [3]
characterized by an insidious clinical onset [4], ﬁxed airﬂow
obstruction on spirometry, and characteristic features on
high-resolution computed tomography. Surgical lung biopsy
is the gold standard but is not often performed because of a
high complication rate [5]. BOS has a dismal prognosis, with a
5-year survival of approximately 13%,which has not improved
signiﬁcantly over the past 2 decades [4,6,7]. Only some sym-
ptomatic patients diagnosed with BOS have been shown to
respond to therapy [7], although prospective clinical trials,
including studies in which early intervention before devel-
opment of symptomatic disease, have yet to be systematically
undertaken. Using the 2005 National Institutes of HealthTransplantation.
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in mortality after diagnosis of BOS [9].
Theprecise etiologyof BOS is unknown. BOSmay represent
a form of chronic GVHD (cGVHD), although biopsy specimens
from patients with BOS do not show the characteristic
epithelial cell apoptosis characteristically associated with
GVHD in other organs [2]. The strong and consistent associa-
tion between cGVHD and BOS in many observational studies,
however, suggests a common immune etiology [6,9-14].
Additional evidence for an alloimmune basis for this disease
includes the similarity between BOS and the clinicopatho-
logical syndrome that frequently develops after pulmonary
allograft [15,16]. This latter syndrome has been shown to be
initiated by alloimmunization [17-20]. In addition, the inci-
dence of BOS in recipients of autologous SCT when condi-
tioned with similar preparative regimens is rare [7].
Previously identiﬁed risk factors for BOS other than
cGVHD include poor pretransplant lung function and older
age [21], aGVHD [21], mobilized peripheral blood progenitor
cells rather than a marrow stem cell source [22], pulmonary
complications post-allograft [23] or idiopathic pneumonia
syndrome [22], conditioning intensity [24], total body irra-
diation (TBI)-based conditioning, methotrexate for GVHD
prophylaxis, busulfan treatment [22], female donor to male
recipient [22], hypogammaglobulinemia [10], and viral in-
fections in the ﬁrst 100 days after allo-SCT [21]. Several
studies have shown T cell depletion to be protective against
cGVHD in general, as well as speciﬁcally reducing NIPS
[23,25] or chronic lung dysfunction [26].
COP represents a distinct form of NIPS characterized by
cough, fever, and dyspnea that is associated with peri-
bronchovascular and subpleural alveolar inﬁltrates on
computed tomography with plugs of granulation tissue in
respiratory bronchioles and alveoli and chronic interstitial
inﬂammation [14]. In the allograft setting, COP has superior
outcomes compared with BOS and idiopathic pneumonia
syndrome [14]. A strong correlation between both aGVHD
and cGVHD and the development of COP has also been
shown, although the precise etiology of COP, as with BOS,
remains unknown.
Given the highmorbidity andmortality rate of BOS, use of
a predictive screening test to identify presymptomatic pa-
tients and institute early immunomodulatory therapy, which
may prevent irreversible structural damage, is an attractive
strategy. A paucity of published data surround the utility of
screening with spirometry for predicting development of
NIPS. It has been suggested that early declines in pulmonary
function using the forced expiratory volume in 1 second
(FEV1.0) measurement on spirometry are associated with
increased risk of airﬂowobstruction at 1 year [27,28], cGVHD,
and a poorer overall survival after allo-SCT [29], but these
studies have not speciﬁcally addressed long-term adverse
respiratory outcomes.
METHODS
We sought to establish clinical predictive factors for the development of
NIPS (deﬁned as BOS or COP). At our institution, routine pulmonary function
screening with spirometry was instituted in 2004, with patients investi-
gated with pretransplant spirometry including measurement of diffusing
capacity for carbon monoxide, followed by repeat measurements at day 100
(D100), 1 year, and 2 years. Because our primary focus was identifying
whether spirometry pretransplant at D100 and 1 year is a useful predictor of
the development of pulmonary complications, cases of idiopathic pneu-
monia syndrome were not considered in our analysis.
All patients had standard clinical and laboratory data prospectively
collected in a central database, which was analyzed to determine whether
early declines in lung function were predictive of later development ofpulmonary dysfunction. Secondary objectives were the identiﬁcation of risk
factors for the development of BOS within our patient cohort.
Conditioning Regimens
Patients included in this analysis received either myeloablative or
reduced-intensity conditioning regimens. Myeloablative conditioning con-
tained either TBI  12 Gy or busulfan  16 mg/kg orally or 12.8 mg/kg by i.v.
infusion combined with cyclophosphamide 120 mg/kg. Most patients with
acute lymphoblastic leukemia were conditioned with fractionated TBI 13.2
Gy and etoposide 60 mg/kg, with palifermin for mucositis prophylaxis.
Reduced-intensity conditioning regimens included ﬂudarabine 125 mg/
m2 and melphalan 140 mg/m2 or ﬂudarabine 90 mg/m2 and cyclophos-
phamide 2250mg/m2. Patients who received umbilical cord unit transplants
were conditionedwith either amyeloablative regimen of ﬂudarabine 75mg/
m2, cyclophosphamide 120 mg/kg, and 12 Gy fractionated TBI from day 3
to day 1 or a nonmyeloablative regimen of ﬂudarabine 200 mg/m2,
cyclophosphamide 50 mg/kg, and 2 Gy TBI.
GVHD Prophylaxis
GVHD prophylaxis at our institution was provided with cyclosporine
and methotrexate. In cord transplants, mycophenolate mofetil 1 g twice
dailywas used in lieu ofmethotrexate. Before 2007, all patients also received
prednisolone .5 mg/kg until day þ35, followed by .25 mg/kg until day þ49.
In vivo T cell depletion was performed in selective cases with antithymocyte
globulin; antithymocyte globulin (Fresenius, Fresenius Biotech GmbH,
Munich, Germany) was used for patients with a serological mismatch at 1 of
the major loci or selected higher risk patients with a molecular mismatch, at
a total dose of 60 mg/kg. Since April 2007, T cell depletion has been per-
formed for all matched unrelated donors (MUDs) or mismatched related
donors using rabbit anti-human antithymocyte globulin (ATG) at a total
dose of 4.5 mg/kg. After 2007, corticosteroid prophylaxis was used for sib-
ling transplants only, with patients receiving MUD transplants instead
receiving in vivo T cell depletion with Thymoglobulin, as outlined above, in
addition to standard cyclosporine A and methotrexate.
Data Capture and Analysis
Patients transplanted between 2004 and 2010 were deemed eligible for
this study, with 257 patients identiﬁed and for whom clinicopathological
data and respiratory function tests were examined. Patients with abnormal
spirometry (FEV1.0 < 75% predicted) developing post-transplant were
identiﬁed; 23 patients were identiﬁed with BOS by National Institutes of
Health criteria [8] or COP. All 23 patients had undergone bronchoscopy with
bronchoalveolar lavage to exclude an infectious etiology. No patient had a
surgical lung biopsy. GVHDwas assessed according to established guidelines
[30,31].
Descriptive statistics were used to identify differences in baseline
characteristics between the group of patients who later developed NIPS and
those who did not. Chi-square tests were used for categorical variables,
whereas t-test or Mann-Whitney tests were used to test for differences for
continuous variables that were normally distributed (age) and not normally
distributed (total number of CD34þ progenitors infused), respectively.
Multivariate analysis was conducted using logistic regression including
variables identiﬁed from the univariate as having a P < .2. Changes in FEV1.0
(DFEV1.0) from baseline to D100, baseline to 1 year, and D100 to 1 year were
calculated. Comparisons were made between the group who later devel-
oped GVHD of the lung and those who did not, using the log rank (Mann-
Whitney) test, and receiver operator characteristic (ROC) curves were
generated to determine the DFEV1.0 time points that provided the best
prediction of later development of NIPS. Time to relapsewas calculated from
time of transplantation to date of relapse or date of documented disease
progression for patients never achieving complete remission. Overall sur-
vival was calculated from time of transplantation until death, with patients
censored at last follow-up. For treatment-related mortality (TRM), patients
were censored at last follow-up or at the time of relapse, because relapse
was considered as a competing risk to TRM. Incidence of cGVHD and aGVHD
were estimated by the cumulative incidence method and thus treated as
time-dependent covariates [32]. Statistical analysis was performed using
Stata version 12 (StataCorp LP, College Station, TX). Approval for this study
was obtained from the Royal Melbourne Hospital institutional review board.
RESULTS
Baseline characteristics of the 257 patients undergoing
SCT are shown in Table 1. Spirometry testing was required
per protocol to be within 2 weeks of D100, of 1 year, and of 2
years. One hundred seventy-ﬁve patients had a D100 FEV1.0,
whereas 164 patients had their per-protocol 1-year FEV1.0.
Table 1
Patient Characteristics in the Transplant Cohort
Characteristic Value
Gender
Male 144 (56.0%)
Female 113 (44.0%)
Median age, yr (range) 46 (17-64)
Indication for transplant
AML 106 (41.2%)
Myelodysplastic syndromes and myeloproliferative
neoplasms
36 (14.0%)
ALL 37 (14.4%)
Lymphoproliferative disorders/plasma cell dyscrasias 70 (27.2%)
Aplastic anemia 8 (3.1%)
Active disease at transplant
Yes 141 (54.9%)
No 116 (45.1%)
Source of stem cells
Marrow 52 (20.2%)
PBPC 196 (76.3%)
Cord 9 (3.5%)
Donor type
Sibling 167 (65.0%)
MUD 79 (30.7%)
Cord 9 (3.5%)
Mismatched related 2 (.8%)
Female donor to male recipient
Yes 38 (15.0%)
No 216 (85.0%)
Median number of CD34þ cells infused, 106/kg (range) 4.6 (.9-14.6)
Conditioning
Myeloablative 159 (61.9%)
Reduced intensity 98 (38.9%)
TBI-based conditioning
Yes 111 (43.2%)
No 146 (56.8%)
Busulfan-based conditioning
Yes 58 (22.3%)
No 199 (77.7%)
Post-transplant corticosteroids for GVHD prophylaxis
Yes 195 (75.8%)
No 45 (17.5%)
Not recorded 15 (6.6%)
T cell depletion
Yes 53 (20.6%)
No 204 (79.4%)
aGVHD
None 131 (54.1%)
Grades I-II 84 (34.7%)
Grades III-IV 27 (11.2%)
cGVHD
None 66 (28.1%)
Limited 62 (26.4%)
Extensive 107 (45.5%)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; PBPC, peripheral blood progenitor cell.
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were thus assessable for cGVHD and lung function deterio-
ration. At the censoring date of October 1, 2012, 152 patients
(59.1%) were alive, with a median follow-up of 44 months to
either death or censoring in all patients and 58 months in
survivors. Relapse occurred in 84 patients (32.7%). Overall
TRM was 17.1% (n ¼ 44). cGVHD developed in 169 patients
(72.8%), with extensive cGVHD in 107 patients (46.1%).
Twenty-three of 235 patients (9.8%) developed NIPS. Of
these, 18 had BOS and 5 had COP.
Timing of Development of NIPS
Signiﬁcant decline in lung function to an FEV1.0 < 75%
predicted developed at a median of 367 days post-transplant
(interquartile range [IQR], 144 to 554 days). Ninety-ﬁve
percent of patients who ultimately developed NIPS haddeveloped signiﬁcant decline in lung function by 2 years
post-transplant (Figure 1). When analysis was restricted to
patients developing BOS only, similar results were obtained
(median, 366 days; IQR, 104 to 439). Twelve cases were
detected by screening (3 at D100, 5 at 1 year, and 4 at 2 years
post-transplant), and 11 cases were detected due to symp-
toms (2 before D100, 3 from D100 to 1 year, 5 from 1 year to
2 years, and 1 > 2 years post-transplant).
The number of patients not developing NIPS who had
follow-up beyond 2 years post-transplant was 162. Median
duration of follow-up beyond 2 years in these 162 patients
was 30 months (IQR, 18 to 46). Only a single case of symp-
tomatic NIPS (a case of BOS) developed beyond 2 years.
Clinical Course of Patients Developing NIPS and
Treatment
Median FEV1.0 at diagnosiswas 58% predicted (IQR, 46% to
71%). Once ﬁxed airﬂow obstruction was established, pro-
gressive deterioration in lung function with time was the
rule; median change in FEV1.0 during follow-up, post-diag-
nosis of NIPS, was 2% per annum (IQR, 7% to 0%). Median
follow-up durationpost-diagnosis of NIPSwas short (median,
1 year; range, 0 to 6 years), however, and when analysis was
restricted to patientswith BOSwho had>6months of follow-
up, median change in FEV1.0 during follow-up was 8% per
annum (IQR,14% to2%). Only 2 patients with BOS showed
improvement in lung function (median change, 7% and 10%
per annum, respectively), and the follow-up period was <1
year in both patients. In contrast, 4 of 5 patients with COP
showed substantial response to treatment (change in FEV1.0
11% to 36% predicted), with normalization of FEV1.0 in
3 patients.
No treatment response was mandated by a fall in FEV1.0.
Where a signiﬁcant fall in FEV1.0 was found, patients were
further evaluated with chest imaging and infectious etiology
was excluded (typically with bronchoscopy and bron-
choalveolar lavage). If the patient was symptomatic or other-
wise met diagnostic criteria for NIPS, treatment was initiated.
Typically, treatment consisted of augmented immunosup-
pression, usually based on systemic corticosteroids, whereas
azithromycin, inhaled corticosteroids, montelukast, and antie
tumor necrosis factor-a therapy were used according to
treating physician discretion. Numbers were too small to
assess the relative beneﬁts of 1 treatment over another.
Of the 23 patients who developed NIPS, 1 patient expe-
rienced disease relapse and 8 patients (35%) died during
follow-up. Cause of death was pulmonary GVHD in 6 patients
and sepsis in 2 patients.
Overall Survival, Disease Relapse, and TRM
At the median follow-up of 44 months, overall survival
was 59.1%. There was a trend toward increased all-cause
mortality in those patients developing NIPS (hazard ratio
[HR], 2.02; 95% conﬁdence interval [CI], .92 to 4.44; P ¼ .080)
and a marked increase in TRM (HR, 5.96; 95% CI, 2.14 to
16.62; P ¼ .001). No statistically signiﬁcant difference in
disease relapse was seen between those with and without
NIPS (HR, .24; 95% CI, .03 to 1.80; P ¼ .166).
Early Decline in Lung Function as a Predictor for Later
Development of Pulmonary GVHD
On univariate analysis, FEV1.0 was the most robust indi-
cator for the later development of NIPS and gave better
discrimination than FEV1.0/forced vital capacity. Diffusion
capacity for carbon monoxide, when corrected for lung
Figure 1. (Left) Cumulative incidence with time of patients developing NIPS. (Right) Cumulative incidence according to whether NIPS was identiﬁed by symptoms or
by screening.
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BOS or COP, often being preserved even in the setting of very
severe obstructive lung disease. Importantly, early decline in
FEV1.0 (DFEV1.0) predicted the later development of NIPS
(Figure 2).
The best predictive values for DFEV1.0, according to ROC
analysis were from baseline to 1 year (area under ROC curve,
C ¼ .86; 95% CI, .77 to .95). However, declines at the other
measurement time points of baseline to D100 (C ¼ .65; 95%
CI, .49 to .81), and from D100 to 1 year (C ¼ .71; 95% CI, .56 to
.87) were also predictive for later development of NIPS
(Figure 3).Figure 2. Median DFEV1.0 between baseline and D100 in patients who developed N
(IQR, 7% to 6%) in unaffected recipients (P ¼ .002). From D100 to 1 year, median DFEV
0% (IQR, 7% to 9%) in unaffected patients (P ¼ .002). Between baseline and 1 year, me
to 3% (IQR, 10% to 4%) in unaffected patients (P < .001).Pretransplant Predictors for the Development of NIPS
On univariate analysis, pretransplant clinical factors that
were signiﬁcant predictors for the later development of NIPS
(Table 2) were busulfan-based conditioning (63.6% of pa-
tients with NIPS versus 18.9% of those without; odds ratio,
7.53; 95% CI, 2.96 to 19.15) and absence of T cell depletion
with Thymoglobulin (P < .001). No patients receiving Thy-
moglobulin in our cohort developed NIPS. No differences in
risk of developing NIPS were found according to indication
for transplant, presence of active disease at the time of
conditioning, age, stem cell source (marrow, peripheral
blood progenitor cells, or cord blood), donor type (sibling,IPS was 12% (interquartile range [IQR], 25% to 1%) compared with 1%
1.0 in patients who developed NIPS was 20% (IQR, 28% to 2%) compared with
dian DFEV1.0 was 19% (IQR, 37% to 6%) in patients developing NIPS versus
Figure 3. ROC curves for prediction of NIPS using change in FEV1.0 at different
assessment time points.
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blative versus reduced-intensity conditioning, TBI-based
conditioning, number of CD34þ progenitors infused,
corticosteroid-based GVHD prophylaxis, or the development
of aGVHD.
On multivariate analysis of pretransplant clinical factors,
only busulfan-based conditioning (odds ratio, 8.87; 95% CI,
3.33 to 23.63; P < .001) was a signiﬁcant predictor for the
development of NIPS, although there was a strong trend to-
ward increased risk with increasing recipient age (odds ratio,
1.05 per year of age; 95% CI, 1.00 to 1.10; P ¼ .054). The use of
T cell depletion was not included in the multivariate model
because it predicted freedom from NIPS perfectly.
DISCUSSION
Nearly 10% of patients in our cohort developed NIPS, with
a 35% TRM rate with relatively short follow-up that was
signiﬁcantly higher than in patients not developing NIPS.
Survival in our cohort of patientswithNIPSwas better than in
some historical series [4,6,7], which likely reﬂects the short
duration of follow-up rather than improved treatment and
supportive care. In keeping with published literature, pa-
tients in our cohortwho developed BOS but not COP had poor
responses to therapy with progressive decline in FEV1.0
during follow-up, which will likely result in ongoing TRM in
this group. Although the overall survival was not different
when compared with the cohort without NIPS, with longer
follow-up, differences may emerge given the expectedTable 2
Univariate Analysis of Predictors of NIPS
Variable No NIPS (n ¼ 212)
Age, mean  SD 42.6  12.5
Active disease at transplant 114 (53.8)
Peripheral blood stem cell source 161 (75.9)
Unrelated donor 71 (33.5)
Female donor to male recipient 29 (14.2)
Median CD34þ progenitors infused, 106/kg (IQR) 5.1 (3.7-6.7)
Myeloablative conditioning 129 (60.9)
TBI-based conditioning 91 (42.9)
Busulfan-based conditioning 40 (18.9)
Corticosteroids for GVHD prophylaxis 172 (86.4)
aGVHD 94 (47.5)
T cell depletion 44 (21.1)
SD indicates standard deviation.
Values are total number of cases, with percent in parentheses, unless otherwise stongoing incidence of nonrelapse mortality in patients with
BOS.
The pathogenesis of NIPS is poorly understood, and it is
unclear whether the different clinicopathological syndromes
(idiopathic pneumonia syndrome, COP, and BOS) represent
distinct entities or a spectrum of clinical behavior related to
immunologically mediated lung injury. The hypothesis that
noninfectious lung injury is immunologically mediated was
supported in our cohort the absence of cases of NIPS in pa-
tients receiving T cell depletionwith Thymoglobulin, with no
cases observed in the 53 patients receiving Thymoglobulin
for GVHD prophylaxis.
The generally poor response to therapy once signiﬁcant
airﬂow obstruction in BOS was established has led to efforts
for early identiﬁcation of patients in whom earlier inter-
vention may lead to better therapeutic response. Here, we
have shown a clear correlation between early decline in
FEV1.0 and the development of NIPS, using relatively infre-
quent spirometry (pretransplant, D100, 1 year, and 2 years).
The timing of onset of NIPS in our cohort was consistent with
previously reported data [9], occurring at a median time of
approximately 1 year post-transplant and occurring rarely
after 2 years; whereas 11 patients were diagnosed with NIPS
due to the development of symptoms before 2 years post-
transplant (as opposed to via screening spirometry), only
1 was diagnosed during a prolonged follow-up period (me-
dian, 30 months) after the 2-year time point. Given the
insidious onset of BOS, if screening had not been performed
at 2 years postallograft, some patients diagnosed at the
2-year screening test may have instead developed symp-
tomatic disease at a later time point; hence, in unscreened
cohorts, onset of symptomatic BOS > 2 years may be more
common than in our cohort. Nonetheless, our data are
consistent with other reported series showing a substantially
lower incidence of BOS beyond 2 years [9].
The median FEV1.0 of 58% (indicating moderate airﬂow
limitation) at diagnosis suggests that substantial declines in
lung function occur before patients come to clinical attention
and emphasizes the importance of regular screening if early
detection is to be achieved. Others have recommended
3-monthly screening until 1 year postallograft [27], but we
suggest continuing this to 2 years postallograft given half the
cases in our cohort developed beyond the 1-year time point.
New-onset NIPS is rare beyond 2 years, and thus any beneﬁts
of continued screening with spirometry beyond this time
point are likely to be diminished. Nonetheless, clinical sur-
veillance should continue as per published guidelines with
further evaluation driven by symptoms [33]. Changes inNIPS (n ¼ 23) P Crude Odds Ratio (95% CI)
46.9  11.0 .110 1.03 (.99-1.07)
10 (43.5) .348 .66 (.28-1.57)
17 (73.9) .801 .90 (.34-2.40)
4 (17.4) .158 .42 (.14-1.28)
4 (17.4) .753 1.28 (.41-4.03)
4.2 (3.3-5.2) .199 .95 (.76-1.18)
14 (60.9) 1.000 1.00 (.41-2.42)
7 (30.4) .275 .58 (.23-1.47)
14 (63.6) < .001 7.53 (2.96-19.15)
17 (73.9) .123 .44 (.16-1.23)
12 (54.6) .529 1.33 (.55-3.21)
0 (0) .010 d
ated.
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the development of NIPS and thus could be omitted from a
screening program. Signiﬁcant declines in FEV1.0 (>10%) [3]
should prompt a thorough diagnostic evaluation, including
high-resolution computed tomography with expiratory
views and, if pulmonary inﬁltrates are seen on imaging,
exclusion of infectious etiology with bronchoscopy. Lesser
changes in FEV1.0 in asymptomatic patients may be followed
with more frequent spirometry, and further declines should
be investigated as outlined above [28]. Asymptomatic pa-
tients identiﬁed to have noninfectious lung injury through
screening are an ideal group for studies of interventions
aimed at preventing the development of ﬁxed airﬂow
obstruction, such as augmented immunosuppression, leu-
kotriene receptor inhibitors, and biological agents.
Finally, it is unclear whether spirometry is the optimal
methodology to identify early immunological lung injury.
Functional testing such as 6-minute walk tests may be more
sensitive. Similarly, it is unknown whether earlier detection
will ultimately lead to improved pulmonary outcomes. These
questions can ultimately only be answered by further, ideally
prospective, studies.
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